EQRx Pronounces Acceptance of Advertising Authorization Utility by the UK’s Medicines and Healthcare Merchandise Regulatory Company for Aumolertinib in EGFR-Mutated Non-small Cell Lung Most cancers

Eqrx, Inc.

Eqrx, Inc.

  • Advertising authorization software is EQRx’s first submission to a regulatory company

  • Utility is predicated on information from pivotal Section 3 AENEAS trial within the first-line remedy of EGFR-mutated non-small cell lung most cancers

CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a brand new kind of pharmaceutical firm dedicated to creating and delivering progressive medicines to sufferers at radically decrease costs, in the present day introduced that the UK (U.Ok.)’s Medicines and Healthcare merchandise Regulatory Company (MHRA) has accepted for evaluate the advertising and marketing authorization software (MAA) for aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), in improvement for the first-line remedy of grownup sufferers with regionally superior or metastatic non-small cell lung most cancers (NSCLC) with activating EGFR mutations and for the remedy of grownup sufferers with regionally superior or metastatic EGFR T790M mutation-positive NSCLC.

“This acceptance of the advertising and marketing authorization software for aumolertinib by the MHRA is our first regulatory submitting and a major milestone for EQRx,” mentioned Melanie Nallicheri, president and chief government officer of EQRx. “Within the U.Ok., roughly 39,000 individuals are identified with lung most cancers every year, and about 10 to fifteen % of those sufferers have EGFR-sensitizing mutations. Given its promising scientific exercise and tolerability profile, we consider that, if authorized, aumolertinib would signify a further and differentiated remedy possibility for sufferers within the U.Ok. who’ve EGFR-mutated NSCLC. We intention to increase entry to 3rd era EGFR inhibitors and look ahead to working with the MHRA because it conducts its evaluate.”

The MAA is primarily supported by information from the pivotal Section 3 AENEAS trial that evaluated aumolertinib within the first-line remedy of regionally superior or metastatic EGFR-mutated NSCLC.1 Outcomes from AENEAS had been not too long ago printed in Journal of Scientific Oncology, and new information from the examine on aumolertinib’s exercise in central nervous system metastases had been offered on the 2022 American Society of Scientific Oncology (ASCO) Annual Assembly.1,2

In 2021, aumolertinib was granted Innovation Passport designation within the U.Ok. by means of the Revolutionary Licensing and Entry Pathway (ILAP) from the ILAP accomplice organizations together with the MHRA. The ILAP was established in early 2021 to speed up the event and entry to promising medicines within the U.Ok., with advantages together with the potential for an accelerated MAA evaluation in addition to rolling evaluate and a steady benefit-risk evaluation.

About Aumolertinib
Aumolertinib is a third-generation, irreversible epidermal development issue receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets each EGFR-sensitizing and T790M resistance mutations with excessive selectivity over wild-type EGFR.3 Aumolertinib is being investigated in a number of ongoing scientific trials, together with research in first- and second-line EGFR-mutated non-small cell lung most cancers (NSCLC). Aumolertinib is authorized by the Nationwide Medical Merchandise Administration (NMPA) of China for each first-line and second-line remedy of sufferers with regionally superior or metastatic EGFR-mutated NSCLC. Aumolertinib was found by Hansoh Prescribed drugs, and EQRx has partnered with Hansoh Prescribed drugs on international improvement of aumolertinib with the aim of increasing entry worldwide. EQRx holds the event and commercialization rights to aumolertinib outdoors of Larger China.

In regards to the AENEAS Trial
AENEAS (NCT03849768) is a randomized, double-blind, multicenter, Section 3 examine designed to guage the efficacy and security of aumolertinib versus gefitinib as first-line remedy for adults with regionally superior or metastatic EGFR-mutated non-small cell lung most cancers (NSCLC). The examine was carried out by Hansoh Prescribed drugs and enrolled 429 sufferers who had been randomized to obtain both aumolertinib (n=214) or gefitinib (n=215). The examine met its major endpoint, demonstrating statistically important enchancment in progression-free survival as in comparison with gefitinib.1 Secondary endpoints embody total survival, total response price and security.

About EQRx

EQRx is a brand new kind of pharmaceutical firm dedicated to creating and delivering progressive medicines to sufferers at radically decrease costs. Launched in January 2020, EQRx is purpose-built, at scale, with a rising catalog of medicines in improvement in high-cost drug classes and rising partnerships with main payers and well being techniques. Leveraging cutting-edge science and know-how and strategic partnerships with stakeholders from throughout the healthcare system, EQRx goals to supply progressive, patent-protected medicines extra effectively and cost-effectively than ever earlier than. To be taught extra, go to www.eqrx.com and comply with us on social media: Twitter: @EQRxIncLinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Drugs™ are emblems of EQRx.

Cautionary Assertion Concerning Ahead-Wanting Statements
This press launch incorporates sure forward-looking statements inside the which means of the federal securities legal guidelines. These forward-looking statements could also be recognized by way of phrases equivalent to “consider,” “undertaking,” “count on,” “anticipate,” “estimate,” “intend,” “design,” “technique,” “future,” “alternative,” “proceed,” “intention,” “aim,” “plan,” “might,” “look ahead,” “ought to,” “will,” “would,” “can be,” “will seemingly outcome,” and related expressions. These forward-looking statements embody, however will not be restricted to, specific or implied statements relating to acquiring regulatory approval for aumolertinib, aumolertinib’s potential as a remedy possibility for NSCLC, EQRx’s capability to increase entry to aumolertinib worldwide with its accomplice Hansoh, and EQRx’s capability to develop and ship progressive medicines at radically decrease costs, amongst others. Ahead-looking statements are predictions, projections and different statements about future occasions which are based mostly on present expectations and assumptions and, in consequence, are topic to dangers and uncertainties. Many elements might trigger precise future occasions to vary materially from the forward-looking statements on this press launch, together with however not restricted to dangers related to the timing and final result of EQRx’s deliberate interactions with MHRA and different regulatory authorities; EQRx’s capability to efficiently display the protection, tolerability, and efficacy of aumolertinib and its different drug candidates; delays of any present and future scientific trials or the event of aumolertinib or EQRx’s different drug candidates; the outcomes of prior scientific trials not being predictive of future outcomes; EQRx’s relationships with Hansoh and its different present and future collaboration companions; EQRx’s capability to in any other case implement its enterprise plans, together with dangers related to its development technique; and different dangers related to its plans to create a brand new sort of pharmaceutical firm,   amongst others. The foregoing listing of things is just not exhaustive. You need to fastidiously think about the foregoing elements and the opposite dangers and uncertainties described within the “Threat Components” part in EQRx’s most up-to-date Annual Report on Kind 10-Ok or Quarterly Report on Kind 10-Q, in addition to another filings with the SEC. These filings establish and deal with different essential dangers and uncertainties that would trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Ahead-looking statements converse solely as of the date they’re made. Readers are cautioned to not put undue reliance on forward-looking statements, and EQRx assumes no obligation and doesn’t intend to replace or revise these forward-looking statements, whether or not because of new info, future occasions, or in any other case.

Buyers and others ought to word that we talk with our traders and the general public utilizing our web site www.eqrx.com, together with, however not restricted to, firm disclosures, investor shows and FAQs, SEC filings, press releases, public convention name transcripts and webcast transcripts. The data that we put up on our web site could possibly be deemed to be materials info. Because of this, we encourage traders, the media and others events to evaluate the data that we put up there regularly. The contents of our web site shall not be deemed included by reference in any submitting with the SEC.

EQRx Contacts:

Dan Budwick
[email protected]
Adjoa Kyerematen
Media Relations Director
[email protected]

[email protected]


1 Lu S, et al. Journal of Scientific Oncology. 2022. doi: 10.1200/JCO.21.02641
2 Lu S, et al. Journal of Scientific Oncology. 40, no. 16_suppl (June 01, 2022) 9096-9096. doi: 10.1200/JCO.2022.40.16_suppl.9096
3 Lu S, et al. J Thorac Oncol. 2022;17(3):411-422. doi: 10.1016/j.jtho.2021.10.024